Health Canada has given its approval for a drug based on cannabis for pain relief in patients afflicted with multiple sclerosis. The drug, named
Sativex, was developed by GW Pharmaceuticals, a UK company, and will be marketed by the German drug giant Bayer. Canada is the first nation in the
world to approve the drug.
TORONTO (CP) - Drug regulators in this country have given market approval to a cannabis-based drug that can be used for relief of neuropathic pain in
adults with multiple sclerosis.
GW Pharmaceuticals and Bayer HealthCare announced Tuesday that Health Canada has approved Sativex, a drug derived from components of the cannabis
plant that is administered via a mouth spray. Canada is the first country in the world to approve the drug, developed by GW Pharmaceuticals and
marketed in this country by pharmaceutical giant Bayer.
"Effective pain control and management are extremely important in a disease like MS," pain expert Dr. Allan Gordon said in a release issued by the
Please visit the link provided for the complete story.
I think this is good news. Keeping medicine from sick people is both immoral and unethical, even if you believe that others could abuse the drug. I
hope other countries, including the U.S., will follow Canada's lead and approve marijuana and cannabis-based drugs for medicinal use.
Being a pill, are the effects gradual instead of the immediate mental shift you get when smoking pot? That's usually what people get addicted to if
they get addicted to pot at all, so I could see how this would be a great alternative to giving people a joint.
For that matter, does it have the mental effects of pot, or just its pain killing properties?
This content community relies on user-generated content from our member contributors. The opinions of our members are not those of site ownership who maintains strict editorial agnosticism and simply provides a collaborative venue for free expression.